title: BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
abstract: Low-grade ovarian serous carcinomas are believed to arise via an adenoma-serous borderline tumor-serous carcinoma sequence. In this study, we found that advanced-stage, low-grade ovarian serous carcinomas both with and without adjacent serous borderline tumor shared similar regions of loss of heterozygosity. We then analyzed 91 ovarian tumor samples for mutations in TP53, BRAF, and KRAS. TP53 mutations were not detected in any serous borderline tumors (n = 30) or low-grade serous carcinomas (n = 43) but were found in 73% of high-grade serous carcinomas (n = 18). BRAF (n = 9) or KRAS (n = 5) mutation was detected in 47% of serous borderline tumors, but among the low-grade serous carcinomas (39 stage III, 2 stage II, and 2 stage I), only one (2%) had a BRAF mutation and eight (19%) had a KRAS mutation. The low frequency of BRAF mutations in advanced-stage, low-grade serous carcinomas, which contrasts with previous findings, suggests that aggressive, low-grade serous carcinomas are more likely derived from serous borderline tumors without BRAF mutation. In addition, advanced-stage, low-grade carcinoma patients with BRAF or KRAS mutation have a better apparent clinical outcome. However, further investigation is needed.
authors.affiliation: Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. kkwong@mdanderson.org
authors.forename: Kwong-Kwok
authors.initials: KK
authors.lastname: Wong
authors.forename: Yvonne T M
authors.initials: YT
authors.lastname: Tsang
authors.forename: Michael T
authors.initials: MT
authors.lastname: Deavers
authors.forename: Samuel C
authors.initials: SC
authors.lastname: Mok
authors.forename: Zhifei
authors.initials: Z
authors.lastname: Zu
authors.forename: Charlotte
authors.initials: C
authors.lastname: Sun
authors.forename: Anais
authors.initials: A
authors.lastname: Malpica
authors.forename: Judith K
authors.initials: JK
authors.lastname: Wolf
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
authors.forename: David M
authors.initials: DM
authors.lastname: Gershenson
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D015894:Genome, Human; D006801:Humans; D009154:Mutation / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D010053:Ovary / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
references.citation: Oncogene. 2005 Feb 3;24(6):1053-65
references.pmid: 15558012
references.citation: Am J Surg Pathol. 2005 Feb;29(2):218-24
references.pmid: 15644779
references.citation: Am J Surg Pathol. 1999 Apr;23(4):397-409
references.pmid: 10199469
references.citation: Obstet Gynecol. 2002 Jan;99(1):3-10
references.pmid: 11777502
references.citation: Nucleic Acids Res. 2004 May 17;32(9):e69
references.pmid: 15148342
references.citation: Am J Surg Pathol. 2002 Sep;26(9):1129-41
references.pmid: 12218569
references.citation: Am J Surg Pathol. 2006 Nov;30(11):1367-71
references.pmid: 17063075
references.citation: Dis Markers. 2007;23(5-6):377-87
references.pmid: 18057521
references.citation: Gynecol Oncol. 2006 Dec;103(3):883-7
references.pmid: 16806438
references.citation: Cancer Res. 2005 Jan 1;65(1):76-84
references.pmid: 15665281
references.citation: Gynecol Oncol. 2009 Jul;114(1):48-52
references.pmid: 19361839
references.citation: Am J Surg Pathol. 2005 Jun;29(6):707-23
references.pmid: 15897738
references.citation: Am J Surg Pathol. 1996 Nov;20(11):1319-30
references.pmid: 8898836
references.citation: Mol Cancer. 2009 Jul 30;8:53
references.pmid: 19642975
references.citation: Am J Surg Pathol. 2008 Nov;32(11):1667-74
references.pmid: 18769340
references.citation: Cancer. 1998 Mar 15;82(6):1096-103
references.pmid: 9506355
references.citation: PLoS Comput Biol. 2006 May;2(5):e41
references.pmid: 16699594
references.citation: Am J Surg Pathol. 2004 Apr;28(4):496-504
references.pmid: 15087669
references.citation: J Pathol. 2004 Mar;202(3):336-40
references.pmid: 14991899
references.citation: Cancer. 1998 Nov 15;83(10):2157-63
references.pmid: 9827720
references.citation: Genomics. 2002 Nov;80(5):465-72
references.pmid: 12408963
references.citation: Cancer Res. 2009 May 1;69(9):4036-42
references.pmid: 19383911
references.citation: Cancer Genet Cytogenet. 2006 Oct 1;170(1):1-8
references.pmid: 16965948
references.citation: Obstet Gynecol. 2006 Aug;108(2):361-8
references.pmid: 16880307
references.citation: Annu Rev Pathol. 2009;4:287-313
references.pmid: 18842102
references.citation: Am J Pathol. 2002 Apr;160(4):1223-8
references.pmid: 11943707
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7273-9
references.pmid: 16243797
references.citation: Cell Death Differ. 2010 Mar;17(3):452-8
references.pmid: 19960022
references.citation: Cancer Res. 2005 Nov 15;65(22):10602-12
references.pmid: 16288054
references.citation: Cancer Res. 2006 Dec 1;66(23):11172-8
references.pmid: 17145861
references.citation: Cancer Cell. 2009 Apr 7;15(4):294-303
references.pmid: 19345328
references.citation: Cancer Res. 2003 Aug 1;63(15):4299-304
references.pmid: 12907594
references.citation: Scand J Clin Lab Invest. 2009;69(4):452-9
references.pmid: 19551557
references.citation: Mod Pathol. 2005 Feb;18 Suppl 2:S19-32
references.pmid: 15761464
references.citation: Adv Anat Pathol. 2009 Sep;16(5):267-82
references.pmid: 19700937
references.citation: Int J Gynecol Pathol. 2003 Jan;22(1):37-41
references.pmid: 12496696
references.citation: J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
references.pmid: 12644542
references.citation: Gynecol Oncol. 2007 Jun;105(3):625-9
references.pmid: 17320156
references.citation: Cell. 2008 Feb 8;132(3):363-74
references.pmid: 18267069
references.citation: Gynecol Oncol. 2008 Mar;108(3):510-4
references.pmid: 18155273
references.citation: Mol Carcinog. 2003 Feb;36(2):53-9
references.pmid: 12557260
references.citation: Bioinformatics. 2003 Dec 12;19(18):2397-403
references.pmid: 14668223
references.citation: Cancer Res. 2004 May 1;64(9):3060-71
references.pmid: 15126342